Home - Translational Breast Cancer Research

2020 Annual Report of TBCR

Greetings from the TBCR Editorial Office! We wish you a happy and fruitful 2021!

TBCR witnessed tremendous developments of Translational Breast Cancer Research, and the hard work of all our editorial board members, guest editors, authors, reviewers, readers as well as our editors. We are very happy to share with you the progress that TBCR gained in 2020. Please click to download the whole report.

Sincerely yours,

Editorial Office
Translational Breast Cancer Research

Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study

Pyrotinib is an irreversible pan-ErbB inhibitor targeting epidermal growth factor receptor, human epidermal growth factor receptor 2 (HER2), and HER4. This randomized, double-blinded phase 3 study evaluated the efficacy and safety of pyrotinib plus capecitabine for HER2-positive local relapsed or metastatic breast cancer.

Breast cancer patients with low estrogen receptor expression gain no significant survival benefit from endocrine therapy: a real-world study from China

Rates of patients receiving endocrine therapy. (A) The annual rate of patients receiving endocrine therapy, and (B) the association between the rate of patients who received endocrine therapy and ER expression levels. ER, estrogen receptor.

Analysis of tumor heterogeneity at the molecular level: a case report of efficacy separation in metastatic breast cancer

Although breast cancer frequently metastasizes to the lungs, rarely breast cancer patients develop separation of the efficacy of different lesions in pulmonary metastases. Differentiation at genetic level between drug-resistant lesion and sensitive lesion may be very challenging but is essential for prognostic and therapeutic considerations.

An advanced refractory breast cancer patient with human epidermal growth factor receptor 2 discordance: a case report

Computed tomography (CT) scan of previous metastases. (A) A metastatic site on the right chest wall was detected (red arrow) in December 2016; (B) the size of the metastasis was found to decrease after treatment with lapatinib plus capecitabine (red arrow). The effectiveness was evaluated as partial response according to the RECIST 1.1 system; (C) the metastatic site on the right chest wall was observed to have increased in size again in February, 2018 (red arrow); (D) a new metastatic site on the right chest wall was discovered in September, 2018 (red arrow), marking the failure of the second-line therapy.

Pyrotinib: a new promising targeted agent for human epidermal growth factor receptor 2-positive breast cancer

Among the different TKIs, in addition to lapatinib, also neratinib and tucatinib have been recently approved by the Food and Drug Administration (FDA) thus becoming two new available targeted treatment options for patients with HER2-positive metastatic breast cancer.

How to optimize real-world study: concept, opportunities, and evidence quality

World Health Statistics 2020 has indicated that, although both life expectancy and healthy life expectancy have increased 8% between 2000 and 2016, non-communicable diseases, which account for 71% of all global deaths, remain a considerable health burden. As an example, breast cancer, the most common cause of cancer deaths among females in 2017, was also responsible for an estimated 626,679 deaths globally in 2018.

AME entered an official partnership with Publons to enhance wide-ranging recognition for reviewers

AME Publishing Company entered an official partnership with Publons, a product of Clarivate Analytic Company (which owns Web of Science, EndNote, ScholarOne, among many others), as of April 2020. Around 60 AME journals’ peer review systems are now integrated seamlessly into the Publons platform (https://publons.com/about/home). The partnership was done to recognize our expert peer reviewers spontaneously for their review contribution.

Editor-in-Chief of TBCR

Dr. Prof. Zefei Jiang, MD, is a Medical Professor of PLA General Hospital, and a supervisor of oncology doctoral candidates.

Dr. Jiang graduated from the First Military Medical University in 1987 and started to work on the field of both clinic and scientific research of oncology. He currently serves as Vice director and Secretary-General of Chinese Society of Clinical Oncology, Chairman of Breast Cancer Expert Committee in Chinese Society of Clinical Oncology, Member of St. Gallen International Consensus of Breast Cancer Experts, Chairman of Breast Disease Branch of Beijing Medical Association.

‹ ›

About tbcr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

General editorial enquiries:
Email: tbcr@amegroups.com
Copyright related enquiries:
Email: permissions@amegroups.com
Commercial sales contact (reprints, advertising, etc.):
Email: sales@amegroups.com

Case Report

A case report of primary squamous cell carcinoma of the breast

Xiaoli Yao, Huihua He, Jingping Yuan, Feng Yao

Translational Breast Cancer Research

2021;

(30 April 2021)

PDF Full Text Reporting Checklist COI Form Open Access

Case Report

T-DM1 for advanced breast cancer after multi-anti-HER2-target therapy: a case report

Langshuang Sun, Lu Gan, Tao Wang

Translational Breast Cancer Research

2021;

(30 April 2021)

PDF Full Text Reporting Checklist COI Form Open Access

Case Report

Benefit with re-challenge of immune checkpoint inhibitors in patient with metastatic triple-negative breast cancer: a case report

Jinmei Zhou, Tao Wang, Li Bian, Jianbin Li, Zefei Jiang

Translational Breast Cancer Research

2021;

(30 April 2021)

PDF Full Text Reporting Checklist COI Form Open Access

Review Article

Cyclin-dependent kinase 4 and 6 inhibitors at the crossroads: the combinational therapeutic strategies in breast cancer—a narrative review

Yiqi Yang, Sha Zhu, Ziyi Fu, Chunxiao Sun, Fan Yang, Tianyu Zeng, Yijia Hua, Shengnan Bao, Xian Gao, Xiang Huang, Wei Li, Yongmei Yin

Translational Breast Cancer Research

2021;

(30 April 2021)

PDF Full Text Reporting Checklist COI Form Open Access

Review Article

Potential biomarkers of resistance to CDK4/6 inhibitors: a narrative review of preclinical and clinical studies

Weiyi Huang, Hongxia Wang

Translational Breast Cancer Research

2021;

(30 April 2021)

PDF Full Text Reporting Checklist COI Form Open Access

Original Article

The role of FOXP3 of interstitial tissue in the pathogenesis of breast cancer

Yu-Juan Xiang, Man Feng, Li-Yuan Liu, Fei Wang, Li-Xiang Yu, Fei Zhou, Shu-Ya Huang, Chao Zheng, Chun-Miao Ye, Wen-Zhong Zhou, Geng-Shen Yin, Zhong-Bing Ma, Liang Li, Qiang Zhang, Qin-Ye Fu, Zhi-Gang Yu

Translational Breast Cancer Research

2021;

(30 April 2021)

PDF Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Editorial

How bone metastases can influence the management of breast cancer

T. John Martin

Translational Breast Cancer Research

2021;

(30 April 2021)

PDF Full Text COI Form Open Access

Editorial

Implementing clinical practice guidelines for breast cancer management: searching for homogeneity in real-life heterogeneity

Francesco Ricci

Translational Breast Cancer Research

2021;

(30 April 2021)

PDF Full Text COI Form Open Access

Case Report

Aggressive breast fibromatosis with axillary accessory breast mastitis mimicking carcinoma: a case report

Yuhong Huang, Nan Shao, Huijuan Shi, Xiaoling Zhang, Yanling Zheng, Ying Lin

Translational Breast Cancer Research

2021;

(31 January 2021)

PDF Full Text Reporting Checklist COI Form Open Access

Review Article

Bone metabolism and the development of denosumab: a narrative review

Xiaohui Niu, Hairong Xu

Translational Breast Cancer Research

2021;

(31 January 2021)

PDF Full Text Reporting Checklist COI Form Open Access

Review Article

The evolution and advances of biomarker use in clinical trials for breast cancer treatment—a narrative review

Jing He, Yijun Jia

Translational Breast Cancer Research

2021;

(31 January 2021)

PDF Full Text Reporting Checklist Peer Review File COI Form Open Access

Review Article

Reprogramming of fatty acid metabolism in breast cancer: a narrative review

Jin Zhao, Fei Xie, Yang Yang, Shu Wang

Translational Breast Cancer Research

2021;

(31 January 2021)

PDF Full Text Reporting Checklist COI Form Open Access

Original Article

Occurrence and distribution of bone metastases in 984 metastatic breast cancer patients

Huangchengyu Nie, Yang Yuan, Jianbin Li, Fengrui Xu, Tao Wang, Li Bian, Zefei Jiang, Shaohua Zhang

Translational Breast Cancer Research

2021;

(31 January 2021)

PDF Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Original Article

Prognosis prediction model for patients with breast cancer with bone metastasis: based on a population database

Kun-Chi Hua

Translational Breast Cancer Research

2021;

(31 January 2021)

PDF Full Text Reporting Checklist COI Form Open Access

Guideline

Chinese expert consensus statement on the clinical diagnosis and treatment of breast cancer bone metastasis and bone related disease

Zefei Jiang, Haibo Wang, Shu Wang, Shusen Wang, Tao Wang, Xiaojia Wang, Jifeng Feng, Jian Liu, Qiang Liu, Tao Sun, Min Yan, Qingyuan Zhang, Jiayi Chen, Quchang Ouyang, Xichun Hu, Cuizhi Geng, Peng Yuan, Yongmei Yin, Ning Liao, Yueyin Pan

Translational Breast Cancer Research

2021;

(31 January 2021)

PDF Full Text Peer Review File COI Form Open Access

Editorial

Expanding therapeutic frontiers in metastatic HER2-positive breast cancer

Sandra Cuellar

Translational Breast Cancer Research

2021;

(31 January 2021)

PDF Full Text COI Form Open Access

Original Article

Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance

Christine Campbell, John Mathew, Ian O. Ellis, Ian Bradbury, Signe Borgquist, Karin Elebro, Andrew R. Green, Pauline Finlay, Julia M. W. Gee, John F. R. Robertson

Translational Breast Cancer Research

2020;

(31 October 2020)

PDF Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Original Article

Multidisciplinary treatment of breast cancer under COVID-19 pandemic

Pin Gao, Shiheng Li, Ying Jin, Zhimin Fan

Translational Breast Cancer Research

2020;

(31 October 2020)

PDF Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Guideline

Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version)

Zefei Jiang, Erwei Song, Xiaojia Wang, Haibo Wang, Xiang Wang, Jiong Wu, Yongmei Yin, Qingyuan Zhang, Jiayi Chen, Wenyan Che, Xiaoyuan Chen, Zhanhong Chen, Peifen Fu, Cuizhi Geng, Baoliang Guo, Chunfang Hao, Yingjian He, Feng Jin, Ning Liao, Nanlin Li, Jian Liu, Qiang Liu, Yunjiang Liu, Yueping Liu, Jie Ma, Jianyun Nie, Yueyin Pan, Chuangui Song, Tao Sun, Kun Wang, Shu Wang, Tao Wang, Xin Wang, Biyun Wang, Shusen Wang, Yongsheng Wang, Ling Xu, Min Yan, Ying Yan, Peng Yuan, Junlan Yang, Fan Zhang, Jun Zhang, Shaohua Zhang, Xuan Zeng, Jianbin Li, Fengrui Xu

Translational Breast Cancer Research

2020;

(31 October 2020)

PDF Full Text COI Form Open Access

Editorial

Treating breast cancer patients in China

Steven A. Narod

Translational Breast Cancer Research

2020;

(31 October 2020)

PDF Full Text COI Form Open Access

View more articles

Currently no content available!

Journal highlight more

Translational Breast Cancer Research is an open access, peer-reviewed journal focusing on cutting-edge development on the transition from preclinical to clinical research concerned with breast cancers, including but not limited to multidisciplinary therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances etc.

Publishing Information

Translational Breast Cancer Research is published by AME Publishing Company

About tbcr

Manuscript Submission

AME Editing Service

Reprint & Permission

Contact us

General editorial enquiries:

Copyright related enquiries:

Commercial sales contact (reprints, advertising, etc.):

Publishing Information